OBCTCD24
Research - Tel Aviv-Yafo, , Israel
OBCTCD24 Employees
OBCTCD24 Details
OBCTCD24 is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-delivered, CD24-based therapeutics: a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. OBCTCD24 is developing a pipeline of CD24-based exosomes aimed at treating COVID-19 with EXO-CD24, a therapeutic directly inhaled to the lungs, as well as a broad range of disease areas, spanning ARDS, respiratory, and autoimmune disease. The EXO-CD24 technology is based on decades of research into the biology of CD24 in the laboratory of Prof. Nadir Arber at the Tel Aviv Sourasky Medical Center.
